Nuveen
ARCT icon

Nuveen’s Arcturus Therapeutics ARCT Stock Holding History

Nuveen’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Hold
52,542
– – ﹤0.01% 3443
2026
Q1 		$406K Buy
52,542
+320
+0.6% +$2.33K ﹤0.01% 2917
2025
Q4 		$320K Hold
52,222
– – ﹤0.01% 3029
2025
Q3 		$962K Hold
52,222
– – ﹤0.01% 2642
2025
Q2 		$679K Sell
52,222
-7,756
-13% -$91.7K ﹤0.01% 2775
2025
Q1 		$635K Sell
59,978
-27,119
-31% -$430K ﹤0.01% 2823
2024
Q4 		$1.48M Sell
87,097
-10,221
-11% -$192K ﹤0.01% 2515
2024
Q3 		$2.26M Buy
97,318
+7,675
+9% +$164K ﹤0.01% 2351
2024
Q2 		$2.18M Sell
89,643
-34,222
-28% -$1.04M ﹤0.01% 2342
2024
Q1 		$4.18M Sell
123,865
-70,817
-36% -$2.51M ﹤0.01% 2081
2023
Q4 		$6.14M Buy
194,682
+336
+0.2% +$7.99K ﹤0.01% 1864
2023
Q3 		$4.97M Buy
194,346
+6,014
+3% +$185K ﹤0.01% 1871
2023
Q2 		$5.4M Buy
188,332
+40,168
+27% +$1.09M ﹤0.01% 1876
2023
Q1 		$3.55M Buy
148,164
+79,617
+116% +$1.43M ﹤0.01% 2075
2022
Q4 		$1.16M Sell
68,547
-41,541
-38% -$724K ﹤0.01% 2629
2022
Q3 		$1.63M Buy
110,088
+1,482
+1% +$24.9K ﹤0.01% 2506
2022
Q2 		$1.71M Buy
108,606
+17,148
+19% +$337K ﹤0.01% 2513
2022
Q1 		$2.24M Sell
91,458
-3,467
-4% -$88.5K ﹤0.01% 2453
2021
Q4 		$3.51M Buy
94,925
+4,292
+5% +$175K ﹤0.01% 2294
2021
Q3 		$4.93M Sell
90,633
-37,539
-29% -$1.68M ﹤0.01% 2218
2021
Q2 		$4.34M Buy
128,172
+49,906
+64% +$1.69M ﹤0.01% 2323
2021
Q1 		$3.23M Sell
78,266
-17,947
-19% -$1.07M ﹤0.01% 2382
2020
Q4 		$4.17M Buy
96,213
+23,936
+33% +$1.62M ﹤0.01% 2166
2020
Q3 		$3.1M Buy
72,277
+9,745
+16% +$484K ﹤0.01% 2160
2020
Q2 		$2.92M Buy
+62,532
New +$2.16M ﹤0.01% 2171

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nuveen's ARCT Position: Q2 2026 in Review

Nuveen held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 52,542 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #3443.

Nuveen first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.14M in Q4 2023. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Nuveen held 52,542 shares of Arcturus Therapeutics worth $353K as of Q2 2026.
  • Nuveen left its Arcturus Therapeutics share count unchanged in Q2 2026.
  • Arcturus Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3443 holding.
  • Nuveen first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Nuveen's Arcturus Therapeutics position peaked at $6.14M in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.